Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors

Table 4 Multivariate analysis of predictors for OS

Variables		P	HR	95.0% CI
Variables		P	HR	Lower	Upper
Drug	Sorafenib vs Sunitinib	0.005	1.283	1.080	1.524
Gender	Male vs Female	0.984	1.002	0.834	1.204
Age	<65 vs > =65	0.784	0.971	0.789	1.196
Pathology	Clear cell vs Non clear cell	0.002	1.498	1.167	1.924
ECOG	0 vs 1 vs 2 vs 3	0.002	1.219	1.078	1.379
Previous nephrectomy	No vs Yes	0.229	0.872	0.697	1.090
MSKCC	Low vs median vs High	0.008	1.354	1.081	1.694
HENG	Low vs median vs High	<0.0001	1.526	1.239	1.880
Number of metastatic organs	1 vs 2 vs 3 vs 4	0.084	1.149	0.982	1.345
Lung metastasis	Yes vs No	0.045	1.285	1.005	1.642
Single lung metastasis	No vs Yes	0.204	0.831	0.624	1.106
Bone metastasis	Yes vs No	0.985	1.002	0.798	1.258
Single bone metastasis	No vs Yes	0.897	0.972	0.634	1.492
Liver metastasis	Yes vs No	0.017	1.398	1.062	1.840
Lymph node metastasis	Yes vs No	0.014	1.289	1.054	1.577
Second line treatment	No vs Yes	0.198	0.886	0.737	1.065

ISSN: 1471-2407